Kezar Life Sciences Inc expected to post a loss of $2.88 a share - Earnings Preview

Reuters03-10

Kezar Life Sciences Inc KZR.OQ KZR.O is expected to show no change in quarterly revenue when it reports results on March 12 (estimated) for the period ending December 31 2024
LSEG's mean analyst estimate for Kezar Life Sciences Inc is for a loss of $2.88 per share.
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 3 "strong buy" or "buy," 3 "hold" and no "sell" or "strong sell."
The mean earnings estimate of analysts was unchanged in the last three months.
Wall Street's median 12-month price target for Kezar Life Sciences Inc is $13.50, above its last closing price of $6.10.

Previous quarterly performance (using preferred earnings measure in US dollars).

QUARTER ENDING	STARMINESMARTESTIMATE®	LSEG IBES ESTIMATE	ACTUAL	BEAT, MET, MISSED	SURPRISE %
Sep. 30 2024	-3.27	-3.15	-2.78	Beat	11.7
Jun. 30 2024	-3.39	-3.20	-2.70	Beat	15.7
Mar. 31 2024	-3.33	-3.33	-3.00	Beat	9.9
Dec. 31 2023	-4.30	-3.80	-4.40	Missed	-15.8
Sep. 30 2023	-3.58	-3.49	-3.20	Beat	8.4
Jun. 30 2023	-3.21	-3.20	-3.40	Missed	-6.2
Mar. 31 2023	-2.90	-2.88	-3.10	Missed	-7.5
Dec. 31 2022		-2.76	-2.50	Beat	9.6

This summary was machine generated March 10 at 11:18 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2518624268?lang=en_US&edition=full_marsco","thumbnail":"","is_english":true,"pubTime":"2025-03-10 19:18","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2518624268","market":"nz","top_or_hot":-1,"title":"Kezar Life Sciences Inc  expected to post a loss of $2.88 a share - Earnings Preview","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>Kezar Life Sciences Inc <kzr.oq> expected to post a loss of $2.88 a share - Earnings Preview </kzr.oq></title></head><body><ul><li><p>Kezar Life Sciences Inc <span>KZR.OQ</span> <span>KZR.O</span> is expected to show no change in quarterly revenue when it reports  results on March 12 (estimated) for the period ending December 31 2024</p></li><li></li><li><p>LSEG's mean analyst estimate for Kezar Life Sciences Inc is for a loss of $2.88 per share. </p></li><li><p>The current average analyst rating on the shares is \"buy\" and the breakdown of recommendations is 3 \"strong buy\" or \"buy,\" 3 \"hold\" and no \"sell\" or \"strong sell.\"  </p></li><li><p>The mean earnings estimate of analysts was unchanged in the last three months. </p></li><li><p>Wall Street's median 12-month price target for Kezar Life Sciences Inc is $13.50, above its last closing price of $6.10. </p></li></ul><p>Previous quarterly performance (using preferred earnings measure in US dollars). </p><table><tbody><tr><td><p>QUARTER ENDING</p></td><td><p>STARMINESMARTESTIMATE®</p></td><td><p>LSEG IBES ESTIMATE </p></td><td><p>ACTUAL</p></td><td><p>BEAT, MET, MISSED</p></td><td><p>SURPRISE %</p></td></tr><tr><td><p>Sep. 30 2024</p></td><td><p>-3.27</p></td><td><p>-3.15</p></td><td><p>-2.78</p></td><td><p>Beat</p></td><td><p>11.7</p></td></tr><tr><td><p>Jun. 30 2024</p></td><td><p>-3.39</p></td><td><p>-3.20</p></td><td><p>-2.70</p></td><td><p>Beat</p></td><td><p>15.7</p></td></tr><tr><td><p>Mar. 31 2024</p></td><td><p>-3.33</p></td><td><p>-3.33</p></td><td><p>-3.00</p></td><td><p>Beat</p></td><td><p>9.9</p></td></tr><tr><td><p>Dec. 31 2023</p></td><td><p>-4.30</p></td><td><p>-3.80</p></td><td><p>-4.40</p></td><td><p>Missed</p></td><td><p>-15.8</p></td></tr><tr><td><p>Sep. 30 2023</p></td><td><p>-3.58</p></td><td><p>-3.49</p></td><td><p>-3.20</p></td><td><p>Beat</p></td><td><p>8.4</p></td></tr><tr><td><p>Jun. 30 2023</p></td><td><p>-3.21</p></td><td><p>-3.20</p></td><td><p>-3.40</p></td><td><p>Missed</p></td><td><p>-6.2</p></td></tr><tr><td><p>Mar. 31 2023</p></td><td><p>-2.90</p></td><td><p>-2.88</p></td><td><p>-3.10</p></td><td><p>Missed</p></td><td><p>-7.5</p></td></tr><tr><td><p>Dec. 31 2022</p></td><td></td><td><p>-2.76</p></td><td><p>-2.50</p></td><td><p>Beat</p></td><td><p>9.6</p></td></tr></tbody></table><p>This summary was machine generated March 10 at 11:18 GMT.  All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Kezar Life Sciences Inc  expected to post a loss of $2.88 a share - Earnings Preview</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nKezar Life Sciences Inc  expected to post a loss of $2.88 a share - Earnings Preview\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-03-10 19:18</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>Kezar Life Sciences Inc <kzr.oq> expected to post a loss of $2.88 a share - Earnings Preview </kzr.oq></title></head><body><ul><li><p>Kezar Life Sciences Inc <span>KZR.OQ</span> <span>KZR.O</span> is expected to show no change in quarterly revenue when it reports  results on March 12 (estimated) for the period ending December 31 2024</p></li><li></li><li><p>LSEG's mean analyst estimate for Kezar Life Sciences Inc is for a loss of $2.88 per share. </p></li><li><p>The current average analyst rating on the shares is \"buy\" and the breakdown of recommendations is 3 \"strong buy\" or \"buy,\" 3 \"hold\" and no \"sell\" or \"strong sell.\"  </p></li><li><p>The mean earnings estimate of analysts was unchanged in the last three months. </p></li><li><p>Wall Street's median 12-month price target for Kezar Life Sciences Inc is $13.50, above its last closing price of $6.10. </p></li></ul><p>Previous quarterly performance (using preferred earnings measure in US dollars). </p><table><tbody><tr><td><p>QUARTER ENDING</p></td><td><p>STARMINESMARTESTIMATE®</p></td><td><p>LSEG IBES ESTIMATE </p></td><td><p>ACTUAL</p></td><td><p>BEAT, MET, MISSED</p></td><td><p>SURPRISE %</p></td></tr><tr><td><p>Sep. 30 2024</p></td><td><p>-3.27</p></td><td><p>-3.15</p></td><td><p>-2.78</p></td><td><p>Beat</p></td><td><p>11.7</p></td></tr><tr><td><p>Jun. 30 2024</p></td><td><p>-3.39</p></td><td><p>-3.20</p></td><td><p>-2.70</p></td><td><p>Beat</p></td><td><p>15.7</p></td></tr><tr><td><p>Mar. 31 2024</p></td><td><p>-3.33</p></td><td><p>-3.33</p></td><td><p>-3.00</p></td><td><p>Beat</p></td><td><p>9.9</p></td></tr><tr><td><p>Dec. 31 2023</p></td><td><p>-4.30</p></td><td><p>-3.80</p></td><td><p>-4.40</p></td><td><p>Missed</p></td><td><p>-15.8</p></td></tr><tr><td><p>Sep. 30 2023</p></td><td><p>-3.58</p></td><td><p>-3.49</p></td><td><p>-3.20</p></td><td><p>Beat</p></td><td><p>8.4</p></td></tr><tr><td><p>Jun. 30 2023</p></td><td><p>-3.21</p></td><td><p>-3.20</p></td><td><p>-3.40</p></td><td><p>Missed</p></td><td><p>-6.2</p></td></tr><tr><td><p>Mar. 31 2023</p></td><td><p>-2.90</p></td><td><p>-2.88</p></td><td><p>-3.10</p></td><td><p>Missed</p></td><td><p>-7.5</p></td></tr><tr><td><p>Dec. 31 2022</p></td><td></td><td><p>-2.76</p></td><td><p>-2.50</p></td><td><p>Beat</p></td><td><p>9.6</p></td></tr></tbody></table><p>This summary was machine generated March 10 at 11:18 GMT.  All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"KZR","symbol_name":"Kezar Life Sciences Inc.","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250310:nL8N3PT0OF:1","article_id":"2518624268","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2518624268","pubTimestamp":1741605485,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Kezar Life Sciences Inc  expected to post a loss of $2.88 a share - Earnings Preview Kezar Life Sciences Inc KZR.OQ KZR.O is expected to show no change in quarterly revenue when it reports  results on","collect":0,"end_time":0,"defaultTopTitle":"","property":["earning"],"viewcount":null,"language":"en","relate_stocks":{"KZR":"Kezar Life Sciences Inc."},"translate_title":"Kezar Life Sciences Inc预计每股亏损2.88美元-收益预览","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"KZR":0.9},"content_text":"Kezar Life Sciences Inc  expected to post a loss of $2.88 a share - Earnings Preview Kezar Life Sciences Inc KZR.OQ KZR.O is expected to show no change in quarterly revenue when it reports  results on March 12 (estimated) for the period ending December 31 2024LSEG's mean analyst estimate for Kezar Life Sciences Inc is for a loss of $2.88 per share. The current average analyst rating on the shares is \"buy\" and the breakdown of recommendations is 3 \"strong buy\" or \"buy,\" 3 \"hold\" and no \"sell\" or \"strong sell.\"  The mean earnings estimate of analysts was unchanged in the last three months. Wall Street's median 12-month price target for Kezar Life Sciences Inc is $13.50, above its last closing price of $6.10. Previous quarterly performance (using preferred earnings measure in US dollars). QUARTER ENDINGSTARMINESMARTESTIMATE®LSEG IBES ESTIMATE ACTUALBEAT, MET, MISSEDSURPRISE %Sep. 30 2024-3.27-3.15-2.78Beat11.7Jun. 30 2024-3.39-3.20-2.70Beat15.7Mar. 31 2024-3.33-3.33-3.00Beat9.9Dec. 31 2023-4.30-3.80-4.40Missed-15.8Sep. 30 2023-3.58-3.49-3.20Beat8.4Jun. 30 2023-3.21-3.20-3.40Missed-6.2Mar. 31 2023-2.90-2.88-3.10Missed-7.5Dec. 31 2022-2.76-2.50Beat9.6This summary was machine generated March 10 at 11:18 GMT.  All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-2","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.32.1","shortVersion":"4.32.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2518624268"}